• Allergies

Ragwitek Generic Name & Formulations

General Description

Short ragweed pollen allergen extract (Ambrosia artemisiifolia) 12 Amb a 1-Unit; sublingual tablets.

Pharmacological Class

Allergen extract.

How Supplied



Generic Availability


Ragwitek Indications


Short ragweed pollen-induced allergic rhinitis, with or without conjunctivitis, confirmed by (+) skin test or in vitro testing for pollen-specific IgE antibodies. Not for immediate relief of allergic symptoms.

Ragwitek Dosage and Administration

Adults and Children

<5yrs: not established. Initiate at least 12 weeks before onset of ragweed pollen season and continue throughout the season. Give 1st dose under physician supervision; observe ≥30 mins for any signs/symptoms of severe allergic reaction; if tolerated, subsequent doses may be taken at home. 5–65yrs: 1 tab daily. Allow complete dissolution under the tongue before swallowing. Avoid food or beverage for 5 mins after dosing.

Ragwitek Contraindications


Severe, unstable, or uncontrolled asthma. History of any severe systemic or local allergic reaction. History of eosinophilic esophagitis.

Ragwitek Boxed Warnings

Boxed Warning

Severe allergic reactions.

Ragwitek Warnings/Precautions


Risk of severe allergic reactions (eg, anaphylaxis, laryngopharyngeal restriction); discontinue if occurs. Prescribe auto-injectable epinephrine for emergency use. Underlying conditions that may reduce survival of a serious allergic reaction after epinephrine use (eg, markedly compromised lung function, severe mast cell disorder, unstable angina, recent MI, significant arrhythmia, uncontrolled HTN). Moderate or severe asthma. Withhold therapy in acute asthma exacerbation; consider discontinuing if recurrent. Consider discontinuation if persistent and escalating adverse reactions in the mouth or throat. Interrupt therapy for oral inflammation or wounds to allow complete healing. Elderly (>65yrs). Pregnancy. Nursing mothers.

Ragwitek Pharmacokinetics

See Literature

Ragwitek Interactions


Concomitant other allergen immunotherapy: not studied; may increase risk of local or systemic adverse reactions. Avoid concomitant drugs that can potentiate or inhibit effects of epinephrine (eg, beta-adrenergic blockers, alpha-adrenergic blockers, ergot alkaloids, TCAs, levothyroxine, MAOIs, chlorpheniramine, diphenhydramine, [cardiac glycosides, diuretics; monitor for arrhythmias]).

Ragwitek Adverse Reactions

Adverse Reactions

Throat irritation, pruritus (oral, ear, tongue), oral paresthesia, mouth edema; children/adolescents: also lip swelling, glossodynia, nausea, oral pain, pharyngeal edema, swollen tongue, upper abdominal pain, stomatitis, enlarged uvula; severe systemic or local allergic reactions, eosinophilic esophagitis (discontinue if occurs).

Ragwitek Clinical Trials

See Literature

Ragwitek Note

Not Applicable

Ragwitek Patient Counseling

See Literature